SCHOTT TPG Invests in SCHOTT Poonawalla to Drive Growth
Deal News | May 06, 2025 | TPG
TPG, a global alternative asset management firm, has announced a strategic investment in SCHOTT Poonawalla, a joint venture between SCHOTT Pharma and the Serum Institute of India (SII). TPG will acquire a 35% stake from SII, while SII will retain a minority interest and SCHOTT Pharma will continue to hold 50% ownership. This partnership aims to drive the next phase of growth for SCHOTT Poonawalla, underscoring its dedication to making India a leading hub in the pharmaceutical sector. SII, known for its vaccine manufacturing prowess, partnered with SCHOTT Pharma, a company specializing in drug containment and delivery solutions, to form SCHOTT Poonawalla. The investment will be funded through TPG Growth and Novo Holdings as their co-investor. With TPG's involvement, SCHOTT Poonawalla is poised for enhanced growth opportunities.
Sectors
- Pharmaceuticals
- Private Equity
Geography
- India – The joint venture focuses on operations in India, reinforcing the country's status as a global pharmaceutical hub.
- Germany – SCHOTT Pharma, a major player in the joint venture, is headquartered in Mainz, Germany.
Industry
- Pharmaceuticals – The article discusses a joint venture involving pharmaceutical giants, focusing on drug containment, delivery solutions, and vaccine production.
- Private Equity – TPG, a global alternative asset management firm, is making a strategic investment in the joint venture, which falls under the domain of private equity investments.
Financials
- 35% – Percentage stake acquired by TPG in SCHOTT Poonawalla from Serum Institute of India.
- EUR 957 million – Revenue generated by SCHOTT Pharma in the fiscal year 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| TPG | Investor | Company | A global alternative asset management firm acquiring a 35% stake in the joint venture. |
| SCHOTT Pharma | Joint Venture Partner | Company | A pioneer in drug containment and delivery solutions holding 50% ownership in the joint venture. |
| Serum Institute of India | Vendor | Company | Selling a 35% stake of its joint venture in SCHOTT Poonawalla to TPG, while retaining a minority interest. |
| SCHOTT Poonawalla | Target Company | Company | A joint venture between SCHOTT Pharma and Serum Institute of India. |
| Novo Holdings | Co-Investor | Company | Participating in funding the investment along with TPG. |